Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacob Robison

Optometrist Ephraim, UT Doctor of Optometry

NPI 1780970582 CMS profile 584958

43 E 450 N, Ephraim, UT 84627

Open in the dashboard

General payments

$3,607

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacob Robison of Ephraim, UT is reported in the CMS Open Payments database as having received $3,607 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,640 18
2024 General $94 6
2023 General $1,324 13
2022 General $158 10
2021 General $151 10
2020 General $90 7
2019 General $151 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacob Robison
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Jacob Robison were reported at $1,640. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Jacob Robison Optometrist median Middle half National median
2019 $151 $159 $67–$371 $163
2020 $90 $72 $29–$165 $114
2021 $151 $125 $46–$292 $132
2022 $158 $162 $66–$374 $149
2023 $1,324 $177 $72–$406 $160
2024 $94 $188 $77–$427 $164
2025 $1,640 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $2,190 42 payments
  2. CooperVision Inc. $1,146 16 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $103 8 payments
  4. Johnson & Johnson Vision Care, Inc. $77 4 payments
  5. Tarsus Pharmaceuticals, Inc. $45 2 payments
  6. Sun Pharmaceutical Industries Inc. $19 1 payment
  7. Bausch & Lomb Americas Inc. $16 1 payment
  8. Carl Zeiss Meditec, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,143 7 payments
  2. Food and Beverage $1,464 68 payments
Products named General payments · program years 2019–2025
  1. AIR OPTIX $1,182 4 payments
  2. MiSight Contact Lens $1,014 8 payments
  3. Dailies Aqua Comfort Plus $660 2 payments
  4. DAILIES TOTAL1 Multifocal $271 1 payment
  5. Precision 1 $170 12 payments
  6. TOTAL30 $158 11 payments
  7. MyDay Contact Lens $119 7 payments
  8. DAILIES $87 7 payments
  9. Acuvue $77 4 payments
  10. Precision7 $62 4 payments
  11. Other $258 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

212

Median for Optometry: 120

Drug cost

$2,882

Median for Optometry: $8,864

Branded share of claims

22.6%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 96 $854
Prednisolone Acetate Generic 21 $576
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 15 $569
Timolol Maleate Generic 34 $291
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 22 $290
Doxycycline Hyclate Generic 13 $156
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $147

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$39,567

Medicare's payments for the services billed

Medicare patients

321

Average age 76

Services billed

654

176 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 40%
Diabetes 33%
Chronic kidney disease 21%
Ischemic heart disease 17%
Depression 17%
Osteoporosis 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record